2型糖尿病相关代谢性肝病的脂肪变与纤维化形态定量评估
该研究在233例2型糖尿病患者的QUID-NASH项目数据中,比较了活检形态定量(SPA与CPA)与非侵入性影像(MRI-PDFF、MRE、VCTE)的关联。结果显示SPA与MRI-PDFF强相关(rho=0.88),CPA与纤维化分期显著相关,提示形态定量可用于常规实践。
要点
- 脂肪变分级与SPA显著相关,SPA与MRI-PDFF的相关系数为0.88。
- 纤维化分期与CPA显著相关,CPA从0期3.17%增至4期18.05%。
- LSM与纤维化分期仅弱至中度相关,MRE的rho为0.26,VCTE的rho为0.52。
核心结论
- 形态定量评估脂肪变和纤维化在2型糖尿病合并MASLD患者中具有相关性,可常规用于疾病特征描述与监测。
研究设计与样本
- 在QUID-NASH项目的233例2型糖尿病患者中,比较活检形态定量(SPA、CPA)与非侵入性影像(MRI-PDFF、MRE、VCTE)的横断面研究。
主要发现
- 脂肪变分级与SPA显著相关(P<.0001),SPA与%PDFF的相关系数为0.88(95%CI 0.82-0.91)。
- SPA中位数从Grade 0的0.85%升至Grade 3的19.85%,MRI-PDFF范围从4.25%至33.67%。
- 纤维化分期与CPA显著相关(P<.0001),CPA从0期的3.17%升至4期的18.05%。
- 纤维化分期与MRE测得的LSM弱相关(rho=0.26;95%CI 0.12-0.39),与VCTE测得的LSM中度相关(rho=0.52;95%CI 0.42-0.61)。
临床怎么用
- 形态定量SPA和CPA易于应用,可在常规实践中辅助表征2型糖尿病合并MASLD患者的脂肪变和纤维化。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver biopsy remains the reference standard for diagnosing steatohepatitis in metabolic dysfunction-associated steatotic liver disease (MASLD), but its use is limited by interobserver variability. Morphometric analysis offers continuous and objective quantification of steatosis and fibrosis, potentially overcoming these limitations. METHODS: We compared morphometric quantification of steatosis and fibrosis to noninvasive imaging in 233 patients with type 2 diabetes mellitus (T2DM) enrolled in the QUID-NASH project. Steatosis was assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF), and liver stiffness by magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE). Morphometry was performed on biopsy slides measuring steatosis proportionate area (SPA) and collagen proportionate area (CPA). RESULTS: Steatosis grade was related to SPA (P < .0001), which was significantly correlated with %PDFF (rho: 0.88; 95% confidence interval [CI], 0.82-0.91). Median SPA increased from 0.85% in Grade 0 to 19.85% in Grade 3; MRI-PDFF values ranged from 4.25% to 33.67%. Fibrosis stage was related to CPA and weakly correlated with liver stiffness measurement (LSM) by MRE (rho: 0.26; 95% CI, 0.12-0.39), and moderately with LSM by VCTE (rho: 0.52; 95% CI, 0.42-0.61). Fibrosis stage was significantly associated with CPA (P < .0001), which increased from 3.17% in stage 0 to 18.05% in stage 4. CONCLUSIONS: Our study demonstrates the relevance of quantitative morphometric assessment of steatosis and fibrosis in patients with T2DM and MASLD. Such an easily applicable approach could be used in routine practice to better characterize 2 cardinal features of the disease and to improve monitoring.
引用
- Fourati O, Manchon P, Garteiser P, et al. Morphometric Quantification of Steatosis and Fibrosis in Metabolic Liver Disease Associated With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2025. PMID: 40962196. doi:10.1016/j.cgh.2025.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。